Paper39963240
Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation.
Shi K and 5 others. Front Pharmacol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation. Papers, record 39963240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39963240
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34045454 | FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/34045454 | PubMed |
| 2 | 36543880 | Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia. | Leukemia | 2023 | https://conductscience.org/library/papers/36543880 | PubMed |
| 3 | 14759363 | The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. | Mol Cell | 2004 | https://conductscience.org/library/papers/14759363 | PubMed |
| 4 | 38230766 | Cancer statistics, 2024. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38230766 | PubMed |
| 5 | 37892567 | A Review of FLT3 Kinase Inhibitors in AML. | J Clin Med | 2023 | https://conductscience.org/library/papers/37892567 | PubMed |
| 6 | 34497236 | [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia]. | Rinsho Ketsueki | 2021 | https://conductscience.org/library/papers/34497236 | PubMed |
| 7 | 38182819 | FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. | Leukemia | 2024 | https://conductscience.org/library/papers/38182819 | PubMed |
| 8 | 33619261 | Acute myeloid leukemia: current progress and future directions. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33619261 | PubMed |
| 9 | 32722298 | Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | Biomedicines | 2020 | https://conductscience.org/library/papers/32722298 | PubMed |
| 10 | 20705759 | FLT3 as a therapeutic target in AML: still challenging after all these years. | Blood | 2010 | https://conductscience.org/library/papers/20705759 | PubMed |
| 11 | 25826077 | FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. | Oncotarget | 2015 | https://conductscience.org/library/papers/25826077 | PubMed |
| 12 | 32021432 | Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/32021432 | PubMed |
| 13 | 31821677 | FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31821677 | PubMed |
| 14 | 31919472 | FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. | Leukemia | 2020 | https://conductscience.org/library/papers/31919472 | PubMed |
| 15 | 30651634 | Targeting FLT3 mutations in AML: review of current knowledge and evidence. | Leukemia | 2019 | https://conductscience.org/library/papers/30651634 | PubMed |
| 16 | 38917943 | Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. | Crit Rev Oncol Hematol | 2024 | https://conductscience.org/library/papers/38917943 | PubMed |
| 17 | 31632141 | Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31632141 | PubMed |
| 18 | 38932630 | A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden. | Leuk Lymphoma | 2024 | https://conductscience.org/library/papers/38932630 | PubMed |
| 19 | 33853292 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. | Haematologica | 2021 | https://conductscience.org/library/papers/33853292 | PubMed |
| 20 | 31473943 | Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. | Int J Hematol | 2019 | https://conductscience.org/library/papers/31473943 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42466468 | FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches. | RSC Adv | 2026 | https://conductscience.org/library/papers/42466468 | PubMed |
| 42144504 | Rational design and comparative docking and simulation of modified FLT3 inhibitors: a study on enhanced binding stability and inhibition potency. | J Mol Model | 2026 | https://conductscience.org/library/papers/42144504 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39963240
GET https://conductscience.org/api/papers/v1/39963240/references?page=2